FDA and EMA accept filings of subcutaneous ofatumumab for the treatment of relapsing Multiple Sclerosis.- Genmab A/S + Novartis
Related news and insights
Phase III CONSONANCE study data of Ocrevus shows benefits in 1-year analysis with multiple sclerosis patients.- Genentech/Roche Genentech/Roche announced new phase III CONSONANCE study data with Ocrevus (ocrelizumab) that show its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS).
Novartis announces that the peer-reviewed journal Neurology and Therapy has published new data on COVID-19 infections in people living with relapsing remitting multiple sclerosis (RRMS) treated with Kesimpta (ofatumumab).
Merck KGaA, a leading science and technology company, announced new real-world data from the MSBase Registry demonstrating Mavenclad (cladribine tablets) had more favourable relapse outcomes and longer time to switch to another disease modifying therapy (DMT) compared to the oral DMTs fingolimod, dimethyl fumarate (DMF) and teriflunomide in relapsing multiple sclerosis (RMS) patients.